基本信息
浏览量:0
职业迁徙
个人简介
Our laboratory's research is focused on the following two major areas:
1) Developing novel adoptive T cell therapy for the treatment of leukemia and lung cancer.
Human CD3+CD4-CD8-CD56- T cells, termed double negative (DN) T cells, compose a small population of peripheral T cells and their function remains largely unclear. Recently, we have developed a novel protocol by which therapeutic quality and quantity of human DN T cells can be obtained from peripheral blood of healthy donors by ex vivo expansion. More importantly, we have demonstrated that these ex vivo propagated human DN T cells have potent anti-tumor function both in vitro and in patient-derived xenograft models. DN T cells effectively target lung cancer and primary leukemic cells, including those that are resistant to chemotherapy while spare normal blood and bone marrow cells. Unlike conventional T cells, infusion of DN T cells does not cause tissue damage or graft-vs.-host disease, supporting the safety of clinical use of DN T cells. Based on these findings, a phase I clinical trial using DN T cells to treat patients with acute myeloid leukemia and are at high risk of disease recurrence has been proved by Health Canada. As cryopreserved DN T cells from one healthy donor can target leukemic cells obtained from different patients in a non-HLA-restricted manner, it is possible to develop DN T cells as "off-the-shelf" living drugs. We are currently investigating the mechanisms by which these DN T cells selectively recognize and kill cancer cells but not normal cells and tissues, and exploring the possibility of using DN T cells either alone or in combination with other therapies to eliminate cancer cells and prevent disease recurrence.
2) Dissecting cellular and molecular mechanisms involved in immunity and tolerance and their relevance in diseases.
The ability to induce unresponsiveness to our own tissue and transplanted organ grafts while retaining immune responses towards viruses and malignant cells has been a dream of immunologists and clinicians for many years. To achieve this goal requires understanding the cellular and molecular mechanisms that control and regulate immune responses. Another research focus of our laboratory is to understand the cellular and molecular mechanisms governing tolerance and immunity and to translate obtained knowledge into novel therapies for immune related diseases. We study the mechanisms by which regulatory T cells, particularly NK-CD3+ CD4 and CD8 double negative (DN Tregs) control immune responses and prevent graft-vs-host disease and transplant rejection.
1) Developing novel adoptive T cell therapy for the treatment of leukemia and lung cancer.
Human CD3+CD4-CD8-CD56- T cells, termed double negative (DN) T cells, compose a small population of peripheral T cells and their function remains largely unclear. Recently, we have developed a novel protocol by which therapeutic quality and quantity of human DN T cells can be obtained from peripheral blood of healthy donors by ex vivo expansion. More importantly, we have demonstrated that these ex vivo propagated human DN T cells have potent anti-tumor function both in vitro and in patient-derived xenograft models. DN T cells effectively target lung cancer and primary leukemic cells, including those that are resistant to chemotherapy while spare normal blood and bone marrow cells. Unlike conventional T cells, infusion of DN T cells does not cause tissue damage or graft-vs.-host disease, supporting the safety of clinical use of DN T cells. Based on these findings, a phase I clinical trial using DN T cells to treat patients with acute myeloid leukemia and are at high risk of disease recurrence has been proved by Health Canada. As cryopreserved DN T cells from one healthy donor can target leukemic cells obtained from different patients in a non-HLA-restricted manner, it is possible to develop DN T cells as "off-the-shelf" living drugs. We are currently investigating the mechanisms by which these DN T cells selectively recognize and kill cancer cells but not normal cells and tissues, and exploring the possibility of using DN T cells either alone or in combination with other therapies to eliminate cancer cells and prevent disease recurrence.
2) Dissecting cellular and molecular mechanisms involved in immunity and tolerance and their relevance in diseases.
The ability to induce unresponsiveness to our own tissue and transplanted organ grafts while retaining immune responses towards viruses and malignant cells has been a dream of immunologists and clinicians for many years. To achieve this goal requires understanding the cellular and molecular mechanisms that control and regulate immune responses. Another research focus of our laboratory is to understand the cellular and molecular mechanisms governing tolerance and immunity and to translate obtained knowledge into novel therapies for immune related diseases. We study the mechanisms by which regulatory T cells, particularly NK-CD3+ CD4 and CD8 double negative (DN Tregs) control immune responses and prevent graft-vs-host disease and transplant rejection.
研究兴趣
论文共 38 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
European journal of immunologyno. 4 (2014): 1143-55
The Journal of Immunologyno. 1_Supplement (2013): 188.5-188.5
引用0浏览0引用
0
0
S. Juvet, Min‐Koo Han,Edward Kim,Ramesh Vanama,Betty Joe,Caroline Jeon, Fengshu Zhao,Alaa Amash,Oyedele Adeyi,Li Zhang
Journal of Immunologyno. 1_Supplement (2011): 168.24-168.24
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn